In Deal Totaling $3.7 Billion, Merck Buys Animal Health Company Antelliq
In Deal Totaling $3.7 Billion, Merck Buys Animal Health Company Antelliq
AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial
AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial
Merck taps Roche for Keytruda companion diagnostic
Merck taps Roche for Keytruda companion diagnostic
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche wins key cancer drug approval, but taking on Merck remains a challenge
RNAi: A Coming of Age Story
RNAi: A Coming of Age Story
Roche’s Tecentriq gets first-line lung cancer approval
Roche’s Tecentriq gets first-line lung cancer approval
AstraZeneca’s Imfinzi fails another phase 3 trial, this time in head and neck cancer
AstraZeneca’s Imfinzi fails another phase 3 trial, this time in head and neck cancer
One more shot at slowing Keytruda’s first-line lung cancer domination
One more shot at slowing Keytruda’s first-line lung cancer domination
Looking into the Crystal Ball: Top Predictions for 2019 by Biopharma Execs
Looking into the Crystal Ball: Top Predictions for 2019 by Biopharma Execs
Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer
Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer
Merck announces innovative MS treatment MAVENCLAD®
Merck announces innovative MS treatment MAVENCLAD®
Pharm Exec’s 2019 Pipeline Report
Pharm Exec’s 2019 Pipeline Report
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
Merck KGaA, Darmstadt, Germany Enters Field of Big Data With Joint Venture With Palantir Technologies
Merck KGaA, Darmstadt, Germany Enters Field of Big Data With Joint Venture With Palantir Technologies
Merck KGaA and Pfizer’s Checkpoint Inhibitor Fails in Late-Stage Ovarian Cancer Study
Merck KGaA and Pfizer’s Checkpoint Inhibitor Fails in Late-Stage Ovarian Cancer Study
